Over the past few years, medications such as Ozempic, Wegovy, and Mounjaro have dominated headlines. Some people describe them as “miracle weight-loss injections,” while others worry about their side effects. So, what’s the truth? Like most medical breakthroughs, the answer lies somewhere in the middle.
These medicines belong to a group of drugs that influence the body’s natural appetite-control system. Ozempic and Wegovy are GLP-1 receptor agonists, while Mounjaro acts on both GIP and GLP-1 receptors. After you eat, your intestines naturally release these hormones to signal that you’re full. The medications mimic these signals, making food leave the stomach more slowly, increasing feelings of fullness, and reducing hunger. Imagine turning down the volume on your brain’s “I’m hungry” alarm, it becomes easier to eat less without constantly battling cravings.
When combined with healthy eating and regular physical activity, clinical trials have shown that these medicines can help people lose around 10-20% of their body weight, depending on the drug, dose, and duration of treatment. For many people living with obesity, this amount of weight loss can significantly improve health.
But the benefits go far beyond the number on the weighing scale. Obesity increases the risk of conditions such as type 2 diabetes, heart disease, stroke, and kidney disease. These medications can improve blood sugar control and, in some people, lower the risk of serious cardiovascular and kidney complications. Perhaps just as importantly, their success has helped change how doctors think about obesity. Instead of viewing it simply as a lack of willpower, obesity is increasingly recognised as a complex, chronic disease influenced by genetics, hormones, metabolism, environment, and lifestyle.
However, these medicines are not magic injections. Most people experience at least some side effects, especially during the first few weeks. Nausea, vomiting, diarrhoea, constipation, and stomach discomfort are the most common. Although uncommon, more serious complications—including pancreatitis, gallbladder disease, and kidney problems-can occur. Another concern is that rapid weight loss may reduce muscle mass as well as body fat, making adequate protein intake and regular strength training important parts of treatment.
There’s another catch: the medicines work only while they’re being taken. Studies show that many people regain a significant amount of lost weight after stopping treatment if healthy eating habits and regular physical activity are not maintained.
So, are these drugs a miracle or a risk? They are neither. They are powerful medical tools that can be life-changing for people who meet medical criteria and use them under professional supervision. But they are not a replacement for balanced nutrition, physical activity, or long-term lifestyle changes.
The real breakthrough isn’t simply that these medicines help people lose weight-it’s that they are changing the way obesity is understood and treated, recognising it as a chronic medical condition that deserves effective, evidence-based care rather than blame.
